Abstract
Background
The American Joint Committee on Cancer (AJCC) eighth edition is based on pancreatic intraepithelial neoplasia-derived pancreatic ductal adenocarcinoma (PDAC), a biologically distinct entity from intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic cancer. The role of nodal disease and the AJCC’s prognostic utility for IPMN-derived pancreatic cancer are unclear. This study aimed to evaluate the prognostic role of nodal disease and the AJCC eighth-edition N-staging for IPMN-derived pancreatic cancer.
Methods
Upfront-surgery patients with IPMN-derived PDAC from four centers were stratified according to the AJCC eighth-edition N stage. Disease characteristics were compared using descriptive statistics, and both overall survival (OS) and recurrence-free survival (RFS) were evaluated using log-rank tests. Multivariable Cox regression was performed to determine the prognostic value of N stage for OS, presented as hazard ratios with 95 % confidence intervals (95 % CIs). A lowest p value log-rank statistic was used to derive the optimal cutoff for node-positive disease.
Results
For 360 patients, advanced N stage was associated with worse T stage, grade, tubular histology, and perineural and lymphovascular invasion (all p < 0.05). The median OS was 98.3 months (95 % CI 82.8–122.0 months) for N0 disease, 27.8 months (95 % CI 24.4–41.7 months) for N1 disease, and 18.1 months (95 % CI 16.2–25.9 months) for N2 disease (p < 0.001). The AJCC N stage was validated and associated with worse OS (N1 [HR 1.64; range, 1.05–2.57], N2 [HR2.42; range, 1.48–3.96]) and RFS (N1 [HR 1.81; range, 1.23–2.68], N2 [HR 3.72; range, 2.40–5.77]). The optimal cutoff for positive nodes was five nodes.
Conclusion
The AJCC eighth-edition N-staging is valid and prognostic for both OS and RFS in IPMN-derived PDAC.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Pancreatic ductal adenocarcinoma (PDAC) is associated with meager survival due to its tendency for local and systemic disease progression, even after surgical resection of the primary tumor.1,2 Multiple clinicopathologic factors such as tumor size, nodal disease, metastatic disease, grade of differentiation, and perineural and lymphovascular invasion have been associated with oncologic outcomes in PDAC.3,4,5,6,7,8 The presence of nodal disease in particular has been consistently and strongly implicated in systemic disease recurrence and poorer survival.7,9,10,11
Currently, the eighth edition of the American Joint Committee on Cancer (AJCC) staging system for pancreas cancer recommends defining nodal disease into three groups: N0 (0 positive nodes), N1 (1–3 positive nodes), and N2 (≥4 positive nodes).12 This is a marked change from the seventh edition, which split N stage into a binary classification of the presence (N1) or absence (N0) of nodal regional lymph node metastasis.13 Numerous studies have validated the AJCC eighth-edition classification for PDAC, demonstrating respectable prognostication performance with varying new recommendations to improve discrimination.3,14,15,16
Existing classifications and validations are largely based on pancreatic intraepithelial neoplasia (PanIN)-derived PDAC, which currently is accepted to be biologically distinct from intraductal papillary mucinous neoplasia (IPMN)-derived PDAC.17 Furthermore, survival outcomes are significantly different between these two distinct entities.18,19 Like PanIN-derived PDAC, the presence of nodal disease is a robust predictor of disease recurrence and survival in IPMN-derived PDAC.20,21,22 In fact, one recent multicenter study reported that the AJCC seventh edition may be more applicable to IPMN-derived PDAC because significant discrimination was not observed in patients with node-positive disease.23
This multi-institutional study aimed to comprehensively investigate the role of nodal disease in IPMN-derived PDAC and to evaluate the prognostic discrimination of the currently used eighth edition of the AJCC N stage classification for PanIN-derived PDAC in IPMN-derived PDAC.
Methods
The study enrolled patients who underwent surgical resection for pathologically confirmed IPMN-derived PDAC at four high-volume international centers including Amsterdam University Medical Center (between 2013 and 2021), Johns Hopkins Hospital (between 1995 and 2021), New York University Langone Health (between 2014 and 2021), and the Regional Academic Cancer Center Utrecht (between 2005 and 2019). The exclusion criteria ruled out concomitant PanIN-derived PDAC arising separately from an adjacent IPMN, receipt of neoadjuvant therapy, gross positive resection margin, missing N stage, metastatic disease at diagnosis, and 90-day postoperative mortality.
Local institutional review board approval was obtained by all the participating centers. The study adhered to the Strengthening and Reporting of Observational Studies in Epidemiology (STROBE) guidelines24 and complied with the 1964 Helsinki Declaration and its later amendments.
Definitions
For this study, IPMN-derived PDAC and not concomitant PDAC was confirmed by specialized local pathologists. These pancreas-specific pathologists at each high-volume center ensured that a direct association of the IPMN with the invasive component was present. The study excluded patients in whom no direct association (no clear pathologic connection) between the IPMN and invasive component was observed. However, in accordance with the international consensus guidelines, the combination of intestinal IPMN and colloid carcinoma inferred that the invasive component was IPMN-derived because concomitant PDAC exclusively shows tubular carcinoma.25
The T stage was evaluated using the size of the invasive component in accordance with the updated international consensus guidelines.25 The AJCC-TNM system eighth edition was evaluated for staging.12 Microscopic evidence of invasive cancer at or within 1 mm of the resection margin was defined as R1. Carbohydrate antigen 19-9 (CA19-9) was defined as non-secreter (<5 U/ml), normal (≥5 and ≤37 U/ml), or elevated (>37 U/ml).
Decisions regarding the use of adjuvant chemotherapy were institution dependent and most often made in a multidisciplinary setting. In general, resected IPMN-derived PDAC was treated like PanIN-derived PDAC given the absence of high-level evidence.
Statistical Analysis
The patients were stratified according to the AJCC eighth-edition N stage (i.e., N0, N1, or N2). Continuous variables were summarized as mean ± standard deviation (SD) or as median with interquartile range (IQR) and compared using an analysis of variance (ANOVA) or Kruskal-Wallis test, respectively. Categorical variables were summarized as counts and percentages and compared using a chi-square or Fisher’s exact test when appropriate.
Overall survival (OS) was defined from the date of surgery to the date of death or last follow-up visit. Recurrence-free survival (RFS) was defined from the date of surgery to the date of death or recurrence, whichever came first, or last follow-up visit. Kaplan–Meier curves were performed to evaluate OS and RFS. Median OS and RFS values were calculated with 95 % confidence intervals (CIs). To compare Kaplan–Meier curves, a log-rank test was used.
Multivariable Cox-regression analysis was used to determine the prognostic value of N stage for OS and RFS. The variables initially included in the analysis were sex, age, CA19-9, T stage, N stage, resection margin, grade, histologic subtype, perineural invasion, lymphovascular invasion, and adjuvant chemotherapy. Backward selection was applied to select the combination of variables most predictive of OS and RFS. An additional multivariable analysis using the prognostic variables derived from the overall analysis was performed to assess the role of adjuvant chemotherapy and the prognostic importance of margin status in OS for patients with N0, N1, and N2 disease. Results are presented as hazard ratios (HRs) and corresponding 95 % CIs. Harrell’s C-statistic was reported to assess performance of the final model. A p value lower than 0.05 was used to define statistical significance.
To assess for a cutoff among the patients with node-positive disease, a lowest p value method using a log-rank test was used with OS as the outcome of interest. Multivariable Cox regression analysis was repeated, replacing AJCC N stage with the calculated optimal lymph node cutoff. Statistical analysis was performed with the R statistical software (version 4.2.3) using the “MaxStat,” “survminer,” “survival,” and “ggplot2” packages.
Results
Study Population
Of the 360 patients enrolled in the study, 56 % (n = 200) were male, 75 % (n = 269) were older than 65 years, and 61 % (n = 220) underwent pancreatoduodenectomy. The median number of harvested lymph nodes was 19 (IQR 14–27). The findings showed N0 disease present in 56 % (n = 201), N1 disease present in 24 % (n = 86), and N2 disease present in 20 % (n = 73) of the patients,. Further clinicopathologic data for the overall study population are summarized in Table S1.
With increasing N stage, worsening T stage (p < 0.001), poorer grade of differentiation (p = 0.006), more tubular than colloid histology (p < 0.001), and increasing prevalence of perineural (p < 0.001) and lymphovascular (p < 0.001) invasion were observed. In N1 and N2 disease, R1 margins also were more common (p < 0.001). Adjuvant chemotherapy was administered to 42 % (n = 81) of the patients with node-negative disease, whereas it was administered to 48 % (n = 40) of the patients with N1 disease, and 51 % (n = 36) of the patients with N2 disease (p = 0.332). These data are summarized in Table 1.
OS and RFS
The median follow-up period for the surviving patients was 41.1 months (IQR 17.5–74.8 months). Using the AJCC eighth-edition N-staging system, the median OS was 98.3 months (95 % CI 82.8–122.0 months) for the patients with N0 disease, 27.8 months (95 % CI 24.4–41.7 months) for the patients with N1 disease, and 18.1 months (95 % CI 16.2–25.9 months) for the patients with N2 disease (p < 0.001). Pairwise comparison showed that the patients with N0 disease had better OS than those with N1 (p < 0.001) or N2 (p < 0.001) disease. The patients with N2 disease had worse OS than those with N1 disease (p = 0.023; Fig. 1)
The median RFS was 72.4 months (95 % CI 48.4–93.9 months) for the patients with N0 disease, 18.6 months (95 % CI 15.4–26.4 months) for the patients with N1 disease, and 11.6 months (95 % CI 9.0–15.1 months) for the patients with N2 disease (p < 0.001). Pairwise comparison showed that the patients with N0 disease had better RFS than those with N1 (p < 0.001) or N2 disease (p < 0.001). The patients with N2 disease had worse RFS than those with N1 disease (p < 0.001) (Fig. 2).
Cox Regression for OS and RFS
Multivariable Cox regression analysis showed that higher AJCC pN-stage classification was associated with worse OS (N1 [HR 1.64; 95 % CI 1.05–2.57; p = 0.029], N2 [HR 2.42; 95 % CI 1.48–3.96; p < 0.001]). Other variables included in the model were age, CA19-9, margin, perineural invasion, and adjuvant chemotherapy. Harrell’s C-statistic for OS in the final model was 0.75. These results are summarized in Fig. 3.
Multivariable Cox regression analysis showed that increasing AJCC pN-stage classification was significantly associated with worse RFS (N1 [HR 1.81; 95 % CI 1.23–2.68; p = 0.003], N2 [HR 3.72; 95 % CI 2.40–5.77; p < 0.001]). Other variables included in the model were CA19-9, margin, perineural invasion, and adjuvant chemotherapy. Harrell’s C-statistic for RFS in the final model was 0.74. These results are summarized in Fig. 4.
Impact of Adjuvant Chemotherapy and Margin Status on OS in Each Nodal Stage
For the N0 patients, worse OS was associated with age older than 65 years (HR 3.01; 95 % CI 1.52–5.96; p = 0.002), elevated CA19-9 (HR 1.91; 95 % CI 1.11–3.29; p = 0.02), R1 margin (HR 2.51; 95 % CI 1.16–5.40; p = 0.019), and perineural invasion (HR 1.79; 95 % CI 1.03–3.12; p = 0.039), whereas adjuvant chemotherapy was not (p = 0.160). For the N1 patients, margin status was not significantly associated with OS (HR 2.45; 95 % CI 0.94–0.42; p = 0.070), whereas adjuvant chemotherapy was associated with improved OS (HR 0.46; 95 % CI 0.23–0.94; p = 0.033). For the N2 patients, again, margin status was not associated with OS (HR 0.78; 95 % CI 0.32–1.91; p = 0.588), whereas adjuvant chemotherapy was associated with improved OS (HR 0.25; 95 % CI 0.11–0.54; p = 0.033).
Cutoffs for Node-Positive Disease
Potential lymph node positivity cutoffs with significant discriminatory ability were two, three, four, five, or six positive lymph nodes (all p < 0.05). The lowest p value was noted at a cutoff of five or more positive lymph nodes. In the Cox regression analysis for OS using the five-lymph-node cutoff, N-stage remained associated with worse survival (N1 [HR 1.59; 95 % CI 1.03–2.44; p = 0.035], N2 [HR 3.00; 95 % CI 1.79–5.05; p < 0.001]). Other variables included in the model were age, CA19-9, margin, perineural invasion, and adjuvant chemotherapy. Harrell’s C-statistic for the final model including the five-lymph-node cutoff was 0.76. These results are summarized in Fig. S1.
In the Cox regression analysis for RFS using the five-lymph-node cutoff, N stage remained associated with worse survival (N1 [HR 1.90; 95 % CI 1.32–2.76; p < 0.001], N2 [HR 4.50; 95 % CI 2.80–7.23; p < 0.001]). Other variables included in the model were CA19-9, margin, perineural invasion, and adjuvant chemotherapy. Harrell’s C-statistic for the final model including the five-lymph-node cutoff model was 0.74. These results are summarized in Fig. S2.
Discussion
The current AJCC staging system for pancreatic cancer is derived from studies and validations mostly composed of PanIN-derived PDAC. Due to a lack of evidence-based studies for IPMN-derived PDAC, its management and prognostication often are based on our more developed and comprehensive understanding of PanIN-derived PDAC.
This study leveraged a multi-institutional experience, investigated the role of N stage in IPMN-derived PDAC, and validated the current AJCC pN stage. We observed that advancing N stage was associated with worsening histopathologic features as well as OS and RFS. We also found that the current eighth-edition AJCC N-staging is valid and provides robust discrimination for IPMN-derived PDAC.
In our study, we found that advancing N stage was associated with worsening histopathologic features, mostly in a stepwise manner. These factors included worsening T stage, grade of differentiation, tubular histologic subtype, and perineural and lymphovascular invasion. This highlights that advanced nodal disease is associated with worse disease biology in IPMN-derived PDAC. A similar trend has been described in PanIN-derived PDAC as well.26,27
Interestingly, the study additionally observed that incidence of an R1 resection margin also was associated with worse nodal disease. This may be partially explained by the trend seen in worsening T stage and more locally aggressive disease. This finding also is consistent with studies investigating PanIN-derived PDAC.26,28 Interestingly, the use of adjuvant chemotherapy did not significantly vary based on N stage, although multiple retrospective studies have observed nodal disease as the best clinicopathologic factor in determining the controversial need for adjuvant chemotherapy.29,30
Recently, Margonis et al.23 evaluated the performance of the seventh and eighth editions of the AJCC staging systems for 275 patients. In their analysis, they found no significant difference in OS in a comparison of patients with N1 and N2 disease (p = 0.497) per the AJCC eighth-edition recommendation. Accordingly, they recommended regrouping patients with N1 and N2 disease, which is concordant with the AJCC seventh-edition recommendation.13,23 However, our more strongly powered study found a significant difference between these two cohorts, thus successfully validating the AJCC eighth-edition N stage classification. Furthermore, our study found multiple potential cutoffs for significant discrimination in positive nodal stage prognostication. The optimal cutoff was found to be five lymph nodes or more for N2 disease, which is just one node greater than the current AJCC N2-stage definition recommends.12 However, the prognostic model performance was comparable with both cutoffs. These data thus support the use of the currently recommended AJCC eighth edition in IPMN-derived PDAC.
Interestingly, the median OS was 98.3 months for the patients with N0 disease, 27.8 months for the patients with N1 disease, and 18.1 months for the patients with N2 disease. The median RFS values for these cohorts were respectively 72.4, 18.6, and 11.6 months. Whereas the patients without nodal disease were observed to have excellent outcomes, the patients with nodal disease had poorer outcomes, comparable with the OS and RFS observed for patients with resected PanIN-derived PDAC.3 This could potentially explain why adjuvant chemotherapy was found to be associated with improved survival for the patients with N1 or N2 disease and not for those with N0 disease, with similar observations for all the patients with PanIN-derived PDAC. This suggests that when patients with IPMN-derived PDAC experience nodal disease, they behave like patients with PanIN-derived PDAC. The biologic underpinnings and clinical implications of this finding need to be explored further.
Nodal disease has been strongly implicated in outcomes for IPMN-derived PDAC in multiple studies.20,22,31,32 The multivariable Cox regression found the AJCC N stage classification to be a significant predictor in modeling prognosis for both OS and RFS. Age, preoperative CA19-9 level, margin status, perineural invasion, and use of adjuvant chemotherapy also emerged as significant prognostic factors. Thus, these data suggest that current the AJCC eighth edition for N-staging is a robust factor that should be used in patient stratification.
In N-stage sub-analysis, we observed that adjuvant chemotherapy was associated with improved outcomes only for patients with nodal disease, as previously described.29,33,34 Additionally, an R1 margin status appears to be associated with poorer survival only for patients with N0 disease, whereas with increasing nodal status, an R0 margin status appears to be less clinically relevant.
Several limitations of the current study should be acknowledged. First, the study included patients who underwent resection over a long study period during which clinical practice and chemotherapy regimens changed. However, this was done to ensure a large study population given the relative infrequency of resected IPMN-derived PDAC. Second, the retrospective nature of this study led to some missing data that may have influenced results. Finally, different surgical and pathologic assessment practices may have existed across participating centers.
Future prospective studies should investigate the role of lymph node station and nodal staging, and centralization of pathologic evaluation may mitigate potential differences in pathologic reporting practices. Nevertheless, the current study represents the largest investigation validating the AJCC eighth edition for N-staging of IPMN-derived PDAC.
Conclusion
This international multi-institutional study examined the role of positive lymph nodes and validated the current AJCC eighth-edition classification for nodal disease in IPMN-derived PDAC. Advancing nodal disease burden is associated with worse tumor biology and emerges as a robust predictor of OS and RFS. The eighth edition of the AJCC N-stage classification is prognostic for both OS and RFS and therefore valid when applied in IPMN-derived PDAC.
REFERENCES
Rompen IF, Levine J, Habib JR, Sereni E, Mughal N, Hewitt DB, et al. Progression of site-specific recurrence of pancreatic cancer and implications for treatment. Ann Surg. 2023. https://doi.org/10.1097/SLA.0000000000006142.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, et al. Multi-institutional validation study of the American Joint Commission on Cancer (8th ed): changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg. 2017;265:185–91.
van Oosten AF, Daamen LA, Groot VP, Biesma NC, Habib JR, van Goor I, et al. Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A bi-institutional validated risk classification. Eur J Surg Oncol. 2023;49:106910.
Epstein JD, Kozak G, Fong ZV, He J, Javed AA, Joneja U, et al. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. J Surg Oncol. 2017;116:658–64.
Kaslow SR, Sacks GD, Berman RS, Lee AY, Correa-Gallego C. Natural history of stage IV pancreatic cancer. Identifying survival benchmarks for curative-intent resection in patients with synchronous liver-only metastases. Ann Surg. 2023;278:e798–804.
Habib JR, Kinny-Koster B, Bou-Samra P, Alsaad R, Sereni E, Javed AA, et al. Surgical decision-making in pancreatic ductal adenocarcinoma: modeling prognosis following pancreatectomy in the era of induction and neoadjuvant chemotherapy. Ann Surg. 2023;277:151–8.
Habib JR, Rompen IF, Campbell BA, Andel PCM, Kinny-Köster B, Damaseviciute R, et al. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. J Natl Cancer Inst. 2024. https://doi.org/10.1093/jnci/djae166.
Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936–45.
Maggino L, Malleo G, Crippa S, Belfiori G, Bannone E, Lionetto G, et al. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: Implications for adjuvant therapy. Br J Surg. 2023;110:973–82.
Habib JR, Rompen IF, Kaslow SR, Grewal M, Andel PCM, Zhang S, et al. Defining the minimal and optimal thresholds for lymph node resection and examination for intraductal papillary mucinous neoplasm-derived pancreatic cancer: A multicenter retrospective analysis. Ann Surg. 2024. https://doi.org/10.1097/SLA.0000000000006295.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth-edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.
Pu N, Yin L, Habib JR, Gao S, Hu H, Zhu Y, et al. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma. Future Oncol. 2019;15:3457–65.
Schouten TJ, Daamen LA, Dorland G, van Roessel SR, Groot VP, Besselink MG, et al. Nationwide validation of the 8th American Joint Committee on Cancer TNM staging system and five proposed modifications for resected pancreatic cancer. Ann Surg Oncol. 2022;29:5988–99. https://doi.org/10.1245/s10434-022-11664-4.
Yin F, Saad M, Xie H, Lin J, Jackson CR, Ren B, et al. Validation of American Joint Committee on Cancer 8(th) edition of TNM staging in resected distal pancreatic cancer. World J Gastrointest Pharmacol Ther. 2020;11:25–39.
Fritz S, Fernandez-del Castillo C, Mino-Kenudson M, Crippa S, Deshpande V, Lauwers GY, et al. Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma. Ann Surg. 2009;249:440–7.
Aronsson L, Bengtsson A, Toren W, Andersson R, Ansari D. Intraductal papillary mucinous carcinoma versus pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Int J Surg. 2019;71:91–9.
Ziogas IA, Rodriguez Franco S, Schmoke N, Meguid C, Murphy C, Al-Musawi M, et al. Comparison of invasive pancreatic ductal adenocarcinoma versus intraductal papillary mucinous neoplasm: A national cancer database analysis. Cancers Basel. 2023;15:1185.
Habib JR, Kinny-Koster B, Amini N, Shoucair S, Cameron JL, Thompson ED, et al. Predictors, patterns, and timing of recurrence provide insight into the disease biology of invasive carcinomas arising in association with intraductal papillary mucinous neoplasms. J Gastrointest Surg. 2022;26:2311–20.
Marchegiani G, Mino-Kenudson M, Ferrone CR, Morales-Oyarvide V, Warshaw AL, Lillemoe KD, et al. Patterns of recurrence after resection of IPMN: Who, when, and how? Ann Surg. 2015;262:1108–14.
Partelli S, Fernandez-Del Castillo C, Bassi C, Mantovani W, Thayer SP, Crippa S, et al. Invasive intraductal papillary mucinous carcinomas of the pancreas: Predictors of survival and the role of lymph node ratio. Ann Surg. 2010;251:477–82.
Margonis GA, Pulvirenti A, Morales-Oyarvide V, Buettner S, Andreatos N, Kamphues C, et al. Performance of the 7th and 8th editions of the American Joint Committee on Cancer staging system in patients with intraductal papillary mucinous neoplasm-associated PDAC: A Multi-institutional analysis. Ann Surg. 2023;277:681–8.
Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. PLoS Med. 2007;4:e297.
Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, Hijioka S, Jang JY, Lennon AM, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology. 2024;24:255–70.
Javed AA, Ding D, Baig E, Wright MJ, Teinor JA, Mansoor D, et al. Accurate nodal staging in pancreatic cancer in the era of neoadjuvant therapy. World J Surg. 2022;46:667–77.
Malleo G, Maggino L, Nobile S, Casciani F, Cacciatori N, Paiella S, et al. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2020;46:1734–41.
Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269:520–9.
Marchegiani G, Andrianello S, Dal Borgo C, Secchettin E, Melisi D, Malleo G, et al. Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: It is time for randomized controlled data. HPB Oxford. 2019;21:596–603.
Mungo B, Croce C, Oba A, Ahrendt S, Gleisner A, Friedman C, et al. Controversial role of adjuvant therapy in node-negative invasive intraductal papillary mucinous neoplasm. Ann Surg Oncol. 2021;28:1533–42. https://doi.org/10.1245/s10434-020-08916-6.
Kaiser J, Scheifele C, Hinz U, Leonhardt CS, Hank T, Koenig AK, et al. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy. Eur J Surg Oncol. 2022;48:1309–20.
D’Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. Intraductal papillary mucinous neoplasms of the pancreas: An analysis of clinicopathologic features and outcome. Ann Surg. 2004;239:400–8.
McMillan MT, Lewis RS, Drebin JA, Teitelbaum UR, Lee MK, Roses RE, et al. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). Cancer. 2016;122:521–33.
Rodrigues C, Hank T, Qadan M, Ciprani D, Mino-Kenudson M, Weekes CD, et al. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020;20:722–8.
Acknowledgment
Ben and Rose Cole PRIA Foundation
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
There are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Habib, J.R., Rompen, I.F., Javed, A.A. et al. Evaluation of AJCC Nodal Staging for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-16055-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1245/s10434-024-16055-5